{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:08:43Z","timestamp":1762956523785,"version":"3.40.3"},"publisher-location":"Cham","reference-count":46,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030719326"},{"type":"electronic","value":"9783030719333"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/5584_2020_606","type":"book-chapter","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T22:04:14Z","timestamp":1608156254000},"page":"39-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Potential of Chimeric Antigen Receptor T-Cells in Cancer Therapy"],"prefix":"10.1007","author":[{"given":"Drashti","family":"Desai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. S.","family":"Gaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin","family":"Shende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,17]]},"reference":[{"issue":"11","key":"606_CR1","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1089\/hum.2017.115","volume":"28","author":"H Abken","year":"2017","unstructured":"Abken H (2017) Driving CARs on the highway to solid cancer: some considerations on the adoptive therapy with CAR T cells. Hum Gene Ther 28(11):1047\u20131060","journal-title":"Hum Gene Ther"},{"issue":"11","key":"606_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","volume":"25","author":"L Alabanza","year":"2017","unstructured":"Alabanza L, Pegues M, Geldres C et al (2017) Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther 25(11):2452\u20132465","journal-title":"Mol Ther"},{"key":"606_CR3","doi-asserted-by":"publisher","first-page":"5474602","DOI":"10.1155\/2016\/5474602","volume":"2016","author":"H Alm\u00e5sbak","year":"2016","unstructured":"Alm\u00e5sbak H, Aarvak T, Vemuri MC (2016) CAR T cell therapy: a game changer in cancer treatment. J Immunol Res 2016:5474602","journal-title":"J Immunol Res"},{"issue":"26","key":"606_CR4","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330","journal-title":"Blood"},{"issue":"10","key":"606_CR5","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V et al (2016) Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 34(10):1112\u20131121","journal-title":"J Clin Oncol"},{"issue":"2","key":"606_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis A, Benthall G, Van Acker HH et al (2018) Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther 26(2):354\u2013365","journal-title":"Mol Ther"},{"issue":"9","key":"606_CR7","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R et al (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106(9):3360\u20133365","journal-title":"Proc Natl Acad Sci U S A"},{"key":"606_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","volume":"4","author":"M Chmielewski","year":"2013","unstructured":"Chmielewski M, Hombach AA, Abken H (2013) Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 4:371","journal-title":"Front Immunol"},{"issue":"7","key":"606_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","volume":"36","author":"A Deol","year":"2010","unstructured":"Deol A, Lum LG (2010) Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 36(7):528\u2013538","journal-title":"Cancer Treat Rev"},{"key":"606_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA et al (2020) \u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19:185\u2013199","journal-title":"Nat Rev Drug Discov"},{"key":"606_CR11","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3389\/fimmu.2018.03180","volume":"9","author":"A Dwivedi","year":"2019","unstructured":"Dwivedi A, Karulkar A, Ghosh S, Rafiq A, Purwar R (2019) Lymphocytes in cellular therapy: functional regulation of CAR T cells. Front Immunol 9:3180","journal-title":"Front Immunol"},{"key":"606_CR12","unstructured":"EU Clinical Trials Register. clinicaltrialsregister.eu"},{"issue":"7643","key":"606_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T et al (2017) Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543(7643):113\u2013117","journal-title":"Nature"},{"key":"606_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fimmu.2018.01409","volume":"9","author":"J Fisher","year":"2018","unstructured":"Fisher J, Anderson J (2018) Engineering approaches in human gamma delta T cells for cancer immunotherapy. Front Immunol 9:1409","journal-title":"Front Immunol"},{"issue":"9","key":"606_CR15","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","volume":"94","author":"M Griffioen","year":"2009","unstructured":"Griffioen M, van Egmond EH, Kester MG, Willemze R, Falkenburg JH, Heemskerk MH (2009) Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 94(9):1316\u20131320","journal-title":"Haematologica"},{"issue":"24","key":"606_CR16","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 86(24):10024\u201310028","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"606_CR17","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368(16):1509\u20131518","journal-title":"N Engl J Med"},{"issue":"1","key":"606_CR18","doi-asserted-by":"publisher","first-page":"e96976","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan S, Posey AD Jr, Shaw C et al (2018) Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight 3(1):e96976","journal-title":"JCI Insight"},{"issue":"7","key":"606_CR19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jvir.2018.03.001","volume":"29","author":"JC Hardaway","year":"2018","unstructured":"Hardaway JC, Prince E, Arepally A, Katz SC (2018) Regional infusion of chimeric antigen receptor T cells to overcome barriers for solid tumor immunotherapy. J Vasc Interv Radiol 29(7):1017\u20131021.e1","journal-title":"J Vasc Interv Radiol"},{"issue":"6382","key":"606_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361\u20131365","journal-title":"Science"},{"issue":"7467","key":"606_CR21","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346\u2013354","journal-title":"Nature"},{"issue":"12","key":"606_CR22","doi-asserted-by":"publisher","first-page":"e0144787","DOI":"10.1371\/journal.pone.0144787","volume":"10","author":"H Karlsson","year":"2015","unstructured":"Karlsson H, Svensson E, Gigg C et al (2015) Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS One 10(12):e0144787","journal-title":"PLoS One"},{"issue":"1","key":"606_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31(1):71\u201375","journal-title":"Nat Biotechnol"},{"issue":"3","key":"606_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn NF, Purdon TJ, van Leeuwen DG et al (2019) CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35(3):473\u2013488.e6","journal-title":"Cancer Cell"},{"issue":"4","key":"606_CR25","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, van Steenbergen S et al (2013) Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21(4):904\u2013912","journal-title":"Mol Ther"},{"issue":"1","key":"606_CR26","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/s41467-019-10565-7","volume":"10","author":"YG Lee","year":"2019","unstructured":"Lee YG, Chu H, Lu Y et al (2019) Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nat Commun 10(1):2681","journal-title":"Nat Commun"},{"issue":"6","key":"606_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF et al (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21(6):581\u2013590","journal-title":"Nat Med"},{"issue":"1","key":"606_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12015-019-09933-z","volume":"16","author":"P Mandpe","year":"2020","unstructured":"Mandpe P, Prabhakar B, Shende P (2020) Role of liposomes-based stem cell for multimodal cancer therapy. Stem Cell Rev Rep 16(1):103\u2013117","journal-title":"Stem Cell Rev Rep"},{"issue":"17","key":"606_CR29","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"MV Maus","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH (2014) Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17):2625\u20132635","journal-title":"Blood"},{"issue":"1","key":"606_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","volume":"19","author":"AN Miliotou","year":"2018","unstructured":"Miliotou AN, Papadopoulou LC (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19(1):5\u201318","journal-title":"Curr Pharm Biotechnol"},{"key":"606_CR31","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3389\/fimmu.2018.02493","volume":"9","author":"MA Morgan","year":"2018","unstructured":"Morgan MA, Schambach A (2018) Engineering CAR-T cells for improved function against solid tumors. Front Immunol 9:2493","journal-title":"Front Immunol"},{"issue":"9","key":"606_CR32","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bmt.2016.17","volume":"51","author":"RJ O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E (2016) Virus-specific T-cell banks for \u2018off the shelf\u2019 adoptive therapy of refractory infections. Bone Marrow Transplant 51(9):1163\u20131172","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"606_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459","journal-title":"N Engl J Med"},{"key":"606_CR34","doi-asserted-by":"publisher","first-page":"119563","DOI":"10.1016\/j.ijpharm.2020.119563","volume":"586","author":"A Patil","year":"2020","unstructured":"Patil A, Narvenker R, Prabhakar B, Shende P (2020) Strategic consideration for effective chemotherapeutic transportation via transpapillary route in breast cancer. Int J Pharm 586:119563","journal-title":"Int J Pharm"},{"issue":"374","key":"606_CR35","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S et al (2017) Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 9(374):eaaj2013","journal-title":"Sci Transl Med"},{"issue":"8","key":"606_CR36","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/leu.2016.373","volume":"31","author":"S Rafiq","year":"2017","unstructured":"Rafiq S, Purdon TJ, Daniyan AF et al (2017) Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia 31(8):1788\u20131797","journal-title":"Leukemia"},{"issue":"3","key":"606_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ (2020) Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17(3):147\u2013167","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"606_CR38","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822\u20131826","journal-title":"J Clin Invest"},{"issue":"2","key":"606_CR39","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40199-019-00291-2","volume":"27","author":"P Shende","year":"2019","unstructured":"Shende P, Basarkar V (2019) Recent trends and advances in microbe-based drug delivery systems. Daru 27(2):799\u2013809","journal-title":"Daru"},{"issue":"5","key":"606_CR40","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018020229","volume":"35","author":"PK Shende","year":"2018","unstructured":"Shende PK, Desai D, Gaud RS (2018) Role of solid-gas interface of nanobubbles for therapeutic applications. Crit Rev Ther Drug Carrier Syst 35(5):469\u2013494","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"2","key":"606_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jocit.2016.08.001","volume":"2","author":"AJ Smith","year":"2016","unstructured":"Smith AJ, Oertle J, Warren D, Prato D (2016) Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. Jour Cell Immunother 2(2):59\u201368","journal-title":"Jour Cell Immunother"},{"issue":"25","key":"606_CR42","doi-asserted-by":"publisher","first-page":"21533","DOI":"10.18632\/oncotarget.4071","volume":"6","author":"DG Song","year":"2015","unstructured":"Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ Jr (2015) A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget 6(25):21533\u201321546","journal-title":"Oncotarget"},{"issue":"17","key":"606_CR43","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","volume":"119","author":"BG Till","year":"2012","unstructured":"Till BG, Jensen MC, Wang J et al (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119(17):3940\u20133950","journal-title":"Blood"},{"key":"606_CR44","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/srep03571","volume":"4","author":"G Zhang","year":"2014","unstructured":"Zhang G, Wang L, Cui H et al (2014) Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep 4:3571","journal-title":"Sci Rep"},{"key":"606_CR45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X (2017) Engineering CAR-T cells. Biomark Res 5:22","journal-title":"Biomark Res"},{"issue":"4","key":"606_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJC et al (2015) Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28(4):415\u2013428. http:\/\/clinicaltrials.gov\/","journal-title":"Cancer Cell"}],"container-title":["Advances in Experimental Medicine and Biology","Cell Biology and Translational Medicine, Volume 12"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2020_606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T13:03:53Z","timestamp":1626786233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/5584_2020_606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030719326","9783030719333"],"references-count":46,"URL":"https:\/\/doi.org\/10.1007\/5584_2020_606","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"17 December 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}